论文部分内容阅读
根据2016年数据统计,目前为止,我国骨关节相关疾病患者已超1亿人。而到一线药品零售端购药、咨询的相关患者,每年约有五千万人左右。近几年随着医疗改革的不断深化,医药分开愈演愈烈。无论是医院药房托管还是两票制导致药价大幅下调,社区药店逐渐成为患者购药分流的主战场。基于此,相关骨关节疾病落地零售终端的群体势必进一步扩大。潜在的市场需求进一步拔高,相关品类的销售与健康服务的天花板更加“遥不可及”。
According to the 2016 statistics, so far, China has over 100 million patients with bone-joint disease. To the first-line drug retail side to buy medicine, consulting related patients, about 50 million people each year. In recent years, with the continuous deepening of medical reform, medicine has intensified. Whether hospital pharmacy hosting or two-vote system led to a substantial reduction in drug prices, community pharmacies gradually become the main battlefield for patients to buy medicine diversion. Based on this, the related retail sales of bone and joint disease groups is bound to further expand the group. Potential market demand further higher, the sales of related categories and health services ceiling more “out of reach ”.